![Michael J. Farrell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael J. Farrell
Investitore di Private Equity presso
Deerfield Management Co. LP (Private Equity)
Profilo
Michael Farrell is a Principal on the External Operations team.
Mr. Farrell joined the Firm in 2016 as an Operations Executive, supporting the day-to-day oversight and management of investments in the Firm’s Private Design and Healthcare Innovations Funds.
Prior to Deerfield, Mr. Farrell was Vice President of Finance at Amarin Corporation, a publicly traded biopharmaceutical company.
Before Amarin, he was Controller at Unigene Laboratories, New American Therapeutics, and Akrimax Pharmaceuticals, and served as Director of Accounting at Reliant Pharmaceuticals.
Mr. Farrell began his career in the financial statement audit practice at Arthur Andersen, during which time he became a Certified Public Accountant.
Mr. Farrell holds a B.S.
in Accounting from the University of Maryland.
Posizioni attive di Michael J. Farrell
| Società | Posizione | Inizio |
|---|---|---|
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Investitore di Private Equity | 01/03/2016 |
Precedenti posizioni note di Michael J. Farrell
| Società | Posizione | Fine |
|---|---|---|
| AMARIN CORPORATION PLC | Direttore Finanziario/CFO | 30/06/2016 |
| UNIGENE LABORATORIES INC | Comptroller/Controller/Auditor | 01/06/2013 |
New American Therapeutics, Inc.
 New American Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapeutic medicines | Comptroller/Controller/Auditor | 01/04/2012 |
Akrimax Pharmaceuticals LLC
 Akrimax Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures medicines for metabolic syndrome | Comptroller/Controller/Auditor | 01/09/2010 |
Formazione di Michael J. Farrell
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
82
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Unigene Laboratories, Inc.
 Unigene Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Designs, delivers, manufactures and develops peptide-based therapeutics | Health Technology |
Amarin Corp. Plc
 Amarin Corp. Plc Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops and commercializes therapeutics to improve cardiovascular health | Health Technology |
Akrimax Pharmaceuticals LLC
Akrimax Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures medicines for metabolic syndrome | Health Technology |
University of Maryland
 University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New American Therapeutics, Inc.
New American Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapeutic medicines | Health Technology |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
